Overexpression of MDM2 has been related to oncogenesis. In this communication, we present evidence to show that MDM2 controls the cell cycle-dependent expression of cyclin A by using a pathway that ensures its timely expression. MDM2 does not inhibit cyclin D or E expression. Silencing of endogenous MDM2 expression elevates cyclin A expression. The p53-binding domain of MDM2 harbors a SWIB region homologous to a conserved domain of a chromosome remodeling factor BRG1-associated protein.
Introduction
The oncoprotein MDM2, coded by the human homologue of the mouse double minute-2 (mdm2) gene, is frequently overexpressed in various human cancers, particularly in breast tumors and carcinomas and soft tissue sarcomas (1) (2) (3) . Amplification of the mdm2 gene enhances the tumorigenic potential of murine cells (4, 5) .
MDM2 interacts with several growth suppressors, including the tumor suppressor p53 and the retinoblastoma susceptibility gene product Rb. These interactions are considered to be possible mechanisms for the oncogenic function of MDM2 (1) (2) (3) . MDM2 recognizes the transactivation domain of p53 and inactivates p53-mediated transcriptional activation (6) (7) (8) (9) (10) . Work from our laboratory showed that this interaction is needed for the inhibition of p53-mediated transactivation (7, 10) . MDM2 also degrades p53 by targeting p53 for ubiquitination (11) (12) (13) .
Although MDM2 has been related to oncogenesis, overexpression of MDM2 at a level similar to that found in cancer cells induces growth arrest in cultured nontransformed cells (14) (15) (16) . Two-to 50-fold overexpression of MDM2 efficiently arrests normal human diploid cells at G 1 (14, 16) . This property of MDM2 is also evidenced in transgenic mice targeted to express MDM2 in breast epithelial cells, which leads to inhibited breast development and morphogenesis (17) . Generation of transgenic mice expressing MDM2 splice variants showed a low success rate and selection for transgenic mice with mutations in the MDM2 splice variant (18) . Tumor-derived cells are often insensitive to the growth-inhibitory effect of MDM2 (14) . Deletion mutants of MDM2 lacking the functional growth-inhibitory domains enhance the tumorigenic potential of NIH3T3 cells (14) . Later studies revealed that splice variants of MDM2 expressed in cancer cells lack the growth-inhibitory domains and inactivate the full-length protein (19) . These observations suggest that the MDM2 splice variants found in cancer cells are incapable of inducing G 1 arrest and may inactivate the growth arrest function of the full-length protein. The dichotomy in the oncogenic and G 1 arrest functions of MDM2 led us to determine the mechanisms for MDM2-mediated growth arrest.
To determine how MDM2 induces G 1 arrest in normal cells and how transformed cells may escape this function, we examined the expression of endogenous G 1 -S cyclins in cells after overexpressing or silencing MDM2. The results of this analysis show that in apparently normal diploid cells, MDM2 inhibits cyclin A expression but not the expression of cyclin D or E. MDM2-mediated down-regulation of cyclin A leads to G 1 arrest, which can be rescued by ectopic expression of cyclin A.
Cell cycle-dependent expression of cyclin A is ensured by a highly orchestrated participation of cyclin-dependent kinases (cdk). The cyclin D-cdk4 inhibitor p16 prevents untimely activation of the cyclin E-dependent kinase and thereby the expression of cyclin A by restricting cyclin E expression and also through redistribution of cdk inhibitors p21 or p27 to the cyclin E-cdk2 complex (20, 21) . Cyclin E-cdk2 releases the chromosome remodeling factor BRG1 from a multicomponent repressor complex, which is known to inhibit cyclin A expression (22) . The tumor suppressor p53 interacts with BRG1 and other associated factors of the BRG1 repressor complex to up-regulate the cdk inhibitor p21, which inhibits cyclin A expression by blocking cyclin E-cdk2 activity. Our data show that MDM2 intercepts this cell cycle-dependent pathway through its p53-binding ability to control cyclin A expression. Transformed cells defective in BRG1, p53, or p16 function are defective in MDM2-mediated cyclin A down-regulation, which may help the cells escape an important growth-regulatory pathway.
Results

MDM2 Inhibits Cyclin A Expression in WI38 Cells
Because MDM2 induces G 1 arrest (14, 16), we determined if MDM2 inhibits expression of endogenous G 1 -S cyclins. Normal diploid WI38 cells were nucleofected with an MDM2 expression plasmid. The cell extracts were analyzed for expression of cyclin A and cyclin E. Western blot and densitometric analysis showed that MDM2 significantly down-regulates the expression of cyclin A ( Fig. 1A ; Supplementary Fig. S1A ) but does not down-regulate cyclin E ( Supplementary Fig. S1B ). Furthermore, quantitative PCR (QPCR) analysis of cDNA prepared from the nucleofected WI38 cells showed that MDM2 down-regulates the cyclin A transcript levels in these cells ( Supplementary Fig. S1C ). This observation suggests that MDM2 overexpression may lead to down-regulation of cyclin A and cell cycle arrest.
MDM2-Mediated Inhibition of Cyclin A Expression Can Be Detected by Confocal Microscopy
Because there should be heterogeneity in the expression levels of endogenous G 1 -S cyclins in asynchronously growing cultured cells, and Western analysis yields an average data, we determined cyclin A expression in normal diploid WI38 cells after ectopic expression of MDM2 by immunostaining and confocal imaging (Fig. 1B) . Normal diploid WI38 cells were transfected with an MDM2 expression plasmid on sterile coverslips. MDM2-overexpressing cells were detected by immunostaining fixed cells with an anti-MDM2 antibody directly coupled with FITC, and endogenous cyclin A was detected with an anticyclin A antibody and a rhodamine-coupled secondary antibody. Transfected cells were also stained with anti-proliferating cell nuclear antigen (PCNA) antibody and rhodamine-coupled secondary antibody as a control. Because cells that have crossed the G 1 -S phase border, but not the G 0 -G 1 , should express cyclin A, both cyclin A-expressing and nonexpressing cells were detected in the untransfected population as expected. However, cells overexpressing MDM2 did not show cyclin A expression. Similar results were obtained in normal mouse embryo fibroblast (MEF) cells (data discussed in Fig. 6B, top) . These results confirm our finding that MDM2 can down-regulate cyclin A expression in normal diploid cells. MDM2 did not significantly alter PCNA levels ( Supplementary Fig. S2 ), suggesting that MDM2 does not inhibit PCNA expression.
MDM2-Mediated Inhibition of Cyclin A Expression Can Be Detected by Flow Cytometry
In an asynchronous population, cells that crossed the G 1 -S phase boundary should express cyclin A, whereas the cells in the G 0 -G 1 phase of the cell cycle should not. It is possible that MDM2-expressing cells are asynchronous, some of which express cyclin A and some do not. Because confocal microscopy yields results of few cells, our confocal analysis may have been unable to find MDM2-overexpressing cells expressing cyclin A. To test this possibility, we determined the percentage of MDM2-expressing cells that show inhibition of cyclin A expression by flow cytometry. After its ectopic expression, we sorted MDM2-overexpressing cells by flow cytometry and determined the expression of G 1 cyclins using methods reported previously (14) (15) (16) . The flow cytometric method has been popularly used for detection and quantitation of protein expression (23) .
WI38 cells were transfected with an MDM2 expression plasmid. MDM2-overexpressing cells were identified by immunostaining with an anti-MDM2 antibody directly coupled with phycoerythrin (PE). Endogenous levels of cyclin A were estimated by immunostaining the cells with an anti-cyclin A antibody directly coupled with FITC. Because not all the cells were transfected successfully, transfected cells overexpressing MDM2 were sorted from untransfected cells containing endogenous levels of MDM2 using flow cytometry, and the endogenous cyclin A levels in the two populations were compared.
A representative result is shown in Fig. 2 . Mock-transfected WI38 cells immunostained with PE-coupled anti-MDM2 antibody and FITC-coupled matched isotype of anti-cyclin A antibody ( Fig. 2A) were used to determine background FITC and PE intensities. Vector-transfected cells or cells transfected with a plasmid expressing an irrelevant protein did not induce growth arrest (14) . Figure 2B shows WI38 cells transfected with MDM2 expression plasmid and immunostained with PE-coupled anti-MDM2 and FITC-coupled anti-cyclin A antibodies. The cells showing PE intensity similar to mock-transfected cells were gated as untransfected cells expressing endogenous levels of MDM2. Successfully transfected, MDM2-overexpressing cells showing higher PE intensity than the untransfected cells were thus identified (Fig. 2B, overexpressed MDM2) .
To quantitate the increase in the level of MDM2 expression over the endogenous level in transfected cells, the PE intensity of cells expressing endogenous levels of MDM2 or overexpressing MDM2 was plotted against cell number (Fig. 2C) . As evident from the figure, the MDM2-overexpressing cells showed 2-to 50-fold increase in MDM2 expression over untransfected cells. Single-parameter plot using mock-transfected cells showed similar results (Supplementary Fig. S3 ). This level of MDM2 expression is well within the range of MDM2 overexpression observed in cancer cells (4, 24) .
Comparative immunostaining with FITC-coupled anticyclin A antibody (Fig. 2D, curve 2 ) as opposed to a FITCcoupled IgG isotype of cyclin A antibody (Fig. 2D, curve 1) identified the cyclin A-expressing cells. The intensity of FITC staining indicating endogenous cyclin A levels in cells expressing endogenous levels of MDM2 (Fig. 2E, curve 2 ) or overexpressing MDM2 (Fig. 2E, curve 3 ) was estimated and plotted against cell number.
In untransfected cells with endogenous MDM2, at least 41% of untransfected cells expressed approximately 8-fold higher cyclin A levels over the background, whereas virtually all (97%) of the transfected (MDM2-overexpressing) cells showed FITC intensity similar to the background level (Fig. 2E, curve 3) . The mean FITC intensity of the MDM2-overexpressing cells is approximately 8-fold lower than that of the untransfected WI38 cells that expressed cyclin A (Fig. 2E , compare curves 3 and 2). This observation suggests that in WI38 cells, MDM2 overexpression drastically inhibits cyclin A expression. An experiment using normal diploid MRC5 cells showed similar results (data not shown). Because cyclin A is required for DNA replication (25, 26) , this result also suggests a precise cell cycle inhibitory step modulated by MDM2. This observation is consistent with our previous report that MDM2 induces G 1 arrest in WI38 or MRC5 cells (14) .
MDM2 Does Not Prevent Cyclin E Expression
Because MDM2 inhibited cyclin A expression, we determined if MDM2 inhibits expression of cyclin E that precedes cyclin A expression during normal cell cycling. As described in the previous experiments, normal diploid WI38 cells were transfected with an MDM2 expression plasmid. Transfected cells overexpressing MDM2 were identified using a PE-coupled anti-MDM2 antibody, and the endogenous level of cyclin E was determined by immunostaining with a FITC-coupled anti-cyclin E antibody.
As in the previous experiment, mock-transfected WI38 cells immunostained with PE-coupled anti-MDM2 antibody and FITC-coupled matched isotype of anti-cyclin E antibody (Fig. 3A) were used to determine background FITC and PE intensities. The cells showing PE intensity similar to mocktransfected cells (Fig. 3A) were gated as untransfected cells (Fig. 3B , Background) and MDM2-overexpressing cells showing higher PE intensity than the untransfected cells were gated as transfected (Fig. 3B, overexpressed MDM2 ). The levels of overexpressed MDM2 (3-to 50-fold over endogenous levels) in transfected cells were similar to the previous experiment (Fig. 3C) .
Cells immunostained with FITC-coupled anti-cyclin E antibody (Fig. 3D, curve 2) showed stronger FITC intensity than the FITC-coupled isotype (Fig. 3D , curve 1), identifying cells expressing cyclin E. Comparison of the FITC-anti-cyclin E staining intensities of MDM2-overexpressing and untransfected cells with endogenous MDM2 (Fig. 3E) showed that the mean FITC intensities of the transfected and untransfected cells did not differ significantly (Fig. 3E , curves 2 and 3), suggesting that MDM2 overexpression did not significantly alter the expression of cyclin E in WI38 cells. These results suggest that MDM2-induced G 1 arrest is an event downstream of cyclin E expression.
Elimination of MDM2 Expression Elevates Endogenous Cyclin A Levels
Because overexpression of MDM2 inhibits cyclin A expression in normal cells, we determined if decrease in MDM2 expression would elevate endogenous levels of cyclin A. However, the absence of MDM2 stabilizes p53 (27) (28) (29) . Silencing of MDM2 expression in normal cells such as WI38 therefore should elevate p53 levels, up-regulating the cdk inhibitor p21 and down-regulating cyclin A expression, masking the effect of silencing MDM2. Indeed, down-regulation of MDM2 expression in WI38 cells using a lentivirus expressing MDM2 shRNA showed drastic up-regulation of the p53 target protein p21 and inefficient silencing of MDM2 (data not shown). To circumvent this problem, we used a H460 cell line that harbors WT p53 and intact p53-inducible pathway (30, 31) but lower p21 transcript levels than WI38 cells ( Supplementary Fig. S4D ). H460 cells were infected with lentiviral vectors expressing shRNA against MDM2 or shRNA against a nonendogenous luciferase transcript as control. After infection for different time periods, the cells were extracted to prepare RNA and cDNA. Levels of MDM2, cyclin A, and cyclin E transcripts were determined by QPCR. Transcript levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were used as an internal control. Our data show that the MDM2 transcript level decreased considerably (4-fold) after 6 days of infection (Fig. 4A ). The decrease in the levels of MDM2 transcript was accompanied by a remarkable (44-to 50-fold) elevation in the level of cyclin A transcripts ( Fig. 4B ) although down-regulation of MDM2 and elevation of cyclin A were detected at an earlier time point (Supplementary Fig. S4A and B). Consistent with our flow cytometric analysis (Fig. 3E) , silencing of MDM2 did not show any increase in the cyclin D ( Supplementary Fig. S4C ) or cyclin E transcript levels (Fig. 4C ). These data indicate that endogenous MDM2 is involved in controlling cyclin A expression but not cyclin D or E. Furthermore, down-regulation of MDM2 in H460 cells showed increase in cell cycle progress (Supplementary Table S1 ).
To determine the effect of silencing MDM2 expression in normal cells, we prepared extracts of early-passage primary MEF cells isolated from isogenic normal, p53 knockout, and p53 and MDM2 double-knockout mice (32) . Cell extracts were subjected to gel electrophoresis and Western blot analysis to analyze and compare endogenous levels of cyclin A. The results of this experiment show that elimination of endogenous p53 expression elevates cyclin A levels approximately 2-fold over normal MEF ( Fig. 4D and E), whereas elimination of both p53 and MDM2 expression increases cyclin A expression 5-fold over normal MEF. This experiment corroborates with our data that endogenous MDM2 negatively regulates cyclin A expression in normal cells. Consistent with this observation, p53 and MDM2 double-knockout MEF cells showed faster proliferation than normal or p53−/− MEF cells (Fig. 4F) . The SWIB Domain of MDM2 Is Responsible for DownRegulation of Cyclin A MDM2 interacts with several cell cycle regulators such as Rb or transcription factor E2F involved in the expression of G 1 -S cyclins, and domains of MDM2 involved in these interactions have been determined previously (33) (34) (35) . These interactions may account for negative regulation of cyclin A by MDM2. Therefore, we determined the domain of MDM2 involved in the down-regulation of cyclin A. Several deletion mutants of MDM2 were tested for their ability to inhibit cyclin A expression. As described above, plasmids expressing MDM2 deletion mutants were transfected into WI38 cells. Endogenous cyclin A levels in untransfected (expressing endogenous MDM2) and transfected (overexpressing the deletion mutants) cells were estimated by flow cytometry and compared as described in the earlier experiments.
Comparative immunostaining with FITC-coupled anticyclin A antibody (Fig. 5A, C , and E, curve 2) as opposed to a FITC-coupled IgG isotype of cyclin A antibody (Fig. 5A, C , and E, curve 1) identified the cyclin A-expressing cells. The intensity of FITC staining indicating endogenous cyclin A levels in cells expressing endogenous levels of MDM2 (Fig. 5B, D , and F, curve 2) or overexpressing MDM2 deletion mutants (Fig. 5B, D , and F, curve 3) was estimated and plotted against cell number. The expression of MDM2 or its deletion mutants was confirmed after sorting PE-or FITC-coupled anti-MDM2 antibody-labeled cells and after performing Western blot analysis ( Supplementary Fig. S5 ). The results of these experiments showed that overexpression of a deletion mutant of MDM2 (Del 491-110) containing the NH 2 -terminal 109 amino acid residues inhibited cyclin A expression drastically in WI38 cells (Fig. 5B , curves 2 and 3). Because this domain of MDM2 is required for its interaction with p53 (7, 10), these results suggest that a domain overlapping the p53 interaction domain of MDM2 is responsible for cyclin A down-regulation in WI38 cells. Because the Rb-interaction domain of MDM2 maps outside the NH 2 -terminal 109 amino acid residues (35) , these data also exclude the possibility that interaction with Rb is needed for MDM2-mediated cyclin A down-regulation.
The p53-interaction domain of MDM2 harbors a SWIB domain (Fig. 5 ), homologous to a conserved domain of a chromosome-remodeling factor BRG1-associated protein, structurally capable of binding to p53 at the MDM2-binding site (36) . BRG1 and its associated factors are known to form a repressor complex that restricts cyclin A expression until released by cyclin E in a cell cycle-dependent fashion (22, 37) . The tumor suppressor p53 binds with BRG1 and several components of this repressor complex to up-regulate p21 expression (38, 39) . The SWIB domain of MDM2 lies within 27 to 102 amino acid residues (36) , which are involved in its interaction with p53. Thus, MDM2 may compete with the BRG1 complex and interfere with the p53-BRG1 interaction, releasing BRG1 and its associated complex for repression of cyclin A. If MDM2-mediated cyclin A repression is a result of releasing BRG1 from p53 interaction by competitive inhibition, the deletion mutant of MDM2 that would not stably interact with p53 but would still retain the major part of the SWIB domain should be able to compete with BRG1 for the common interaction site on p53 to interfere with p53-BRG1 interaction. However, deletion mutants of MDM2 lacking the SWIB domain should not inhibit cyclin A expression.
To test the contribution of the SWIB domain in MDM2-mediated cyclin A down-regulation, we chose two NH 2 -terminal deletion mutants of MDM2, one of which (Del 1-58) harbors a major part (amino acid residues 58 to 102) of the SWIB domain, whereas the other (Del 1-120) lacks the SWIB domain. Both mutants are incapable of making a stable interaction with p53 (7, 10). As described above, plasmids expressing the MDM2 deletion mutants were transfected into WI38 cells. Endogenous cyclin A levels in untransfected (expressing endogenous MDM2) and transfected (overexpressing the deletion mutants) cells were estimated and compared. The results of these experiments showed that overexpression of the deletion mutant Del 1-58 that harbors part of the SWIB domain retained the ability to down-regulate cyclin A expression (Fig. 5D , curves 2 and 3), whereas overexpression of the deletion mutant Del 1-120 did not interfere with cyclin A expression (Fig. 5F , curves 2 and 3). These results implicate the SWIB domain of MDM2 in cyclin A down-regulation.
MDM2
Requires the Chromosome Remodeling Factor BRG1 and the Tumor Suppressor p53 to DownRegulate Cyclin A If the SWIB domain of MDM2 competes with the BRG1 complex for the MDM2-binding site on p53 to repress cyclin A expression, MDM2 should not be able to down-regulate cyclin A expression in the absence of BRG1 or p53. To test this possibility, a BRG1-specific siRNA (or a control siRNA) was cotransfected with an MDM2 expression plasmid in WI38 cells. MDM2-expressing cells were immunostained with a FITC-coupled anti-MDM2 antibody; cyclin A was detected by a rhodamine-coupled anti-cyclin A antibody; and the ability of the BRG1 siRNA to silence BRG1 expression was determined by immunostaining the transfected cells with a rhodaminecoupled anti-BRG1 antibody. The immunostained cells were analyzed by confocal microscopy as described in Materials and Methods. The results (Fig. 6A) show that whereas overexpression of MDM2 in the presence of control RNA (scrambled RNA) inhibited cyclin A expression (top), silencing of Brg1 indeed released inhibition of cyclin A expression by MDM2 (bottom). Successful silencing of BRG1 is shown on the right panel. These results suggest that MDM2 requires BRG1 to inhibit cyclin A expression.
We next determined whether MDM2 requires p53 to down-regulate cyclin A. An MDM2 expression plasmid was transfected into normal and p53−/− MEF seeded onto glass coverslips. The cells were fixed and subsequently immunostained with a FITC-coupled anti-MDM2 antibody and rhodaminecoupled anti-cyclin A antibody. Transfected MEF cells were also stained with anti-PCNA antibody and rhodamine-coupled secondary antibody as a control. The results in Fig. 6B show that whereas cyclin A is down-regulated in MDM2-expressing normal MEF cells (top), cyclin A is coexpressed with MDM2 in p53−/− MEF (bottom). Flow cytometric analysis of cyclin A expression in p53−/− MEF-overexpressing MDM2 generated similar results (data not shown). These observations suggest that although a stable MDM2-p53 interaction is not essential for the ability of MDM2 to down-regulate cyclin A (Fig. 5D ), MDM2 requires p53 for this function. As in the case of WI38 cells, MDM2 did not significantly alter PCNA levels ( Supplementary Fig. S6 ) in MEF cells, suggesting that MDM2 does not inhibit PCNA expression.
The cdk4 Inhibitor p16 Cooperates with MDM2 to Inhibit Cyclin A Expression
Cell cycle-dependent cyclin A expression has been shown to be restricted by the cyclin D-cdk4 inhibitor p16, which restricts expression and activation of cyclin E-cdk2 activity. Cyclin E-cdk2 in turn releases cyclin A expression from Brg1-Rb-mediated repression (22) . In cells lacking expression of p16, cyclin E is expressed and the cyclin E-cdk2 inhibitor p21 relocates to the cyclin D-cdk4 complex, releasing cyclin E-cdk2 activity, and, in turn, cyclin A expression by the phosphorylation of RB and BRG1 (22) . Therefore, in the absence of p16, MDM2-mediated release of the BRG1 complex from p53 may not repress cyclin A expression effectively due to the presence of active cyclin E-cdk2.
To test the above hypothesis, we determined whether silencing of p16 expression interferes with MDM2-mediated cyclin A down-regulation. A p16-specific siRNA (or a scrambled siRNA sequence) was cotransfected with MDM2 expression plasmid in WI38 cells. The efficacy of the siRNA was checked by Western blot analysis of p16 (Fig. 6C, right) . MDM2-expressing cells were immunostained with a FITC-coupled anti-MDM2 antibody; cyclin A was detected by a rhodamine-coupled anti-cyclin A antibody; and the cells were analyzed by confocal microscopy. The results (Fig. 6C) show that overexpression of MDM2 in the presence of nonspecific scrambled RNA inhibited cyclin A expression (Fig. 6C, si control) , but not in the presence of p16-specific siRNA (Fig. 6C, si p16) . Furthermore, in a similar experiment using p16−/− MEF cells, MDM2 overexpression did not lead to down-regulation of cyclin A expression in p16−/− MEF cells (Supplementary Fig. S7 ). These results indicate that silencing of p16 expression interferes with MDM2-mediated cyclin A down-regulation, suggesting involvement of p16 in MDM2-mediated regulation of cyclin A expression.
The Cyclin A Down-Regulatory Domain of MDM2 Induces G 1 Arrest in Normal Diploid Cells
Because MDM2 down-regulates cyclin A expression in normal diploid cells such as WI38, MRC5, or primary MEF, and cyclin A is required for DNA replication (25, 26) , we tested whether the cyclin A down-regulatory domain of MDM2 is sufficient to induce G 1 arrest in normal diploid WI38 or MRC5 cells.
To determine the growth-regulatory function of the cyclin A inhibitory domain of MDM2, WI38 or MRC5 cells were transfected with a plasmid expressing MDM2 Del 491-110 harboring the cyclin A inhibitory domain (Fig. 5) . Cells expressing Del 491-110 were detected by immunostaining with an anti-MDM2 antibody against an NH 2 -terminal epitope of MDM2 (N20) and a FITC-coupled secondary antibody. The mocktransfected cells were immunostained similarly to estimate background to gate the cell population expressing Del 491-110 and were then stained with propidium iodide (Fig. 7A) . Flow cytometric separation of Del 491-110-expressing WI38 cells is shown in Fig. 7B . As estimated by the FITC intensity, the transfected cells showed 2-to 40-fold increase in MDM2. The cells expressing Del 491-110 were gated and their propidium iodide intensities were plotted against cell count to generate a DNA histogram. The DNA histogram of the untransfected cells expressing endogenous MDM2 was generated similarly and compared with the histogram of the Del 491-110-expressing cells (Fig. 7C) . Our data suggest that Del 491-110 expression resulted in a drastic decrease (24-6.6%) in the number of cells crossing the G 1 -to S-phase boundary.
Thus, the cyclin A inhibitory domain of MDM2 is capable of inducing G 1 arrest in WI38 cells. Similar expression of Del 491-110 in normal human diploid MRC5 cells (Fig. 7D) showed comparable growth arrest. These results indicate that the cyclin A inhibitory domain of MDM2 situated within the NH 2 -terminal 109 amino acid residues can induce G 1 arrest in normal human diploid cells. Overexpression of full-length MDM2 induced cell cycle arrest in WI38 cells as we reported previously (Supplementary Fig. S8A; ref. 14) . Consistent with our previous report, MDM2 deletion mutant Del 1-120 also induced cell cycle arrest because it harbors p53-independent growth arrest function (Supplementary Fig. S8B; ref. 14) .
Overexpression of Cyclin A Rescues Cells from MDM2-Mediated G 1 Arrest
If MDM2-mediated cyclin A down-regulation causes G 1 arrest, overexpression of cyclin A should rescue WI38 cells from the G 1 arrest mediated by the cyclin A down-regulatory domain of MDM2. This was tested in WI38 cells transfected with the Del 491-110 expression plasmid in the presence or absence of a plasmid expressing human cyclin A. Cells expressing Del 491-110 were detected by a PE-labeled anti-MDM2 antibody and gated as described previously. Levels of cyclin A expression were determined by immunostaining with a FITC-coupled anti-cyclin A antibody and background staining was detected by a FITC-coupled IgG isotype of anti-cyclin A antibody. DNA was stained with 7-aminoactinomycin D (7-AAD). Levels of cyclin A expression in cells expressing Del 491-110 or endogenous MDM2 were quantitated by the intensity of FITCanti-cyclin A staining and was compared by single-parameter curves plotting FITC intensity against cell number (Fig. 8A  and B) . Intensities of 7-AAD were plotted against cell count to generate DNA histograms of the gated cells expressing Del 491-110 or only endogenous MDM2 (Fig. 8C and D) . Our data show that consistent with our observation shown in Figs. 2 and 7 , cells expressing Del 491-110 alone inhibit cyclin A expression (Fig. 8A, curves 1 and 2) and induce G 1 arrest as (Fig. 8C, compare curves 1 and  2 ). When cotransfected with the cyclin A expression plasmid, WI38 cells expressing Del 491-110 also expressed cyclin A at a level comparable with the endogenous levels of cyclin A (Fig. 8B compare curves 1 and 3) and failed to show G 1 arrest (Fig. 8D, compare curves 1 and 3) . These data show that cyclin A expression can rescue Del 491-110-mediated G 1 arrest, implicating that MDM2-mediated down-regulation of cyclin A expression leads to cell cycle arrest.
Tumor-Derived or Immortal Cells Lacking p53 or p16 Often Escape the Cyclin A Down-Regulatory Function of MDM2
Our data suggest that at least one consequence of MDM2 overexpression in normal diploid cells is down-regulation of cyclin A and G 1 arrest. Furthermore, the regulators of the cell cycle-dependent cyclin A expression such as BRG1, p53, and p16 are involved in this function. It is known that deletions of BRG1, p53, and/or p16 mutations are frequent events in cancer cells (40) (41) (42) . Therefore, we determined if cancer cells defective in expressing p53, p16, or BRG1 could escape MDM2-mediated down-regulation of cyclin A and the consequent G 1 arrest.
Flow cytometric experiments, as described previously, were done to determine how MDM2 modulates cyclin A expression in H1299, NIH3T3, 21PT, or MCF-7 cell lines that do not express functional p53, p16, or BRG1. NIH3T3 cells harbor deletion of the p16/p19 gene, whereas H1299 cells harbor the methylated p16 gene (16, (43) (44) (45) . H1299 and 21PT cells lack functional p53, whereas H1299 cells do not express the functional BRG1 (30, 42, 46) .
A representative experiment done with H1299 cells is shown in Fig. 9 . H1299 cells were transfected with an MDM2 expression plasmid and immunostained with PEcoupled anti-MDM2 and FITC-coupled anti-cyclin A antibodies to estimate the MDM2 expression and consequent change in the levels of endogenous cyclin A. As described previously, mock transfected H1299 cells were immunostained similarly to detect endogenous levels of MDM2 and cyclin A, and FITCcoupled isotype of cyclin A was used to determine background immunostaining.
Flow cytometric measurement of PE intensity showed that transfected H1299 cells expressed MDM2 efficiently, with majority of the cells expressing 4-to 50-fold MDM2 over background levels (Fig. 9A ). Comparative immunostaining with FITC-coupled anti-cyclin A antibody and FITC-coupled IgG isotype identified the endogenous levels of cyclin A in mocktransfected H1299 cells (Fig. 9B, curves 1 and 2) . However, the levels of cyclin A expression in MDM2-overexpressing H1299 (Fig. 9C ) cells did not differ significantly from the respective untransfected cells expressing endogenous levels of MDM2, suggesting that MDM2 overexpression did not alter cyclin A expression in these cells. Immortal NIH3T3 or breast cancer-derived 21PT or MCF-7 cells showed similar results (ref. 14; data not shown). This observation suggests that MDM2 fails to inhibit cyclin A expression in immortal or cancer cells that do not express functional p53, BRG1, or p16.
To test whether the cyclin A inhibitory domain of MDM2 can induce G 1 arrest in H1299 cells, the deletion mutant of MDM2, Del 491-110, was overexpressed in H1299 cells. The transfected (Del 491-110-expressing) and untransfected (endogenous MDM2) cells were sorted as described in the case of WI38 cells, and their DNA histograms were generated. Unlike WI38 or MRC5 cells, overlay of the histograms of Del 491-110 expressing and untransfected cells (expressing endogenous MDM2) show that Del 491-110 did not induce G 1 arrest in H1299 cells (Fig. 9D) . Similar results were obtained in NIH3T3, 21PT, and MCF-7 cells (14; data not shown). Consistent with the observation that silencing of p53, BRG1, or p16 attenuates MDM2-mediated cyclin A down-regulation in normal diploid cells, attenuation of the cyclin A inhibitory function of MDM2 in cancer cells defective in expressing p53, BRG1, and p16 argues that cancer cells can escape the MDM2-mediated growth arrest that constitutes an important safety barrier in normal cells. Consistent with the data shown in Fig. 9 and in our previous report (14) , H1299 cells exhibited an inefficient cell cycle arrest mediated by full-length MDM2 compared with WI38 cells (Supplementary Table S2 ).
Discussion
In the present report, we show experimental evidences that MDM2 inhibits expression of cyclin A in apparently normal human diploid cells such as WI38 (Figs. 1 and 2 ), MRC5 (data not shown), or primary MEF cells (Fig. 6B ). MDM2-mediated cyclin A down-regulation prevents onset of the S phase in such cells (Fig. 7) . Because MDM2 does not prevent expression of cyclin E (Figs. 3 and 4) or D (Supplementary Fig. S4D ), MDM2-mediated cyclin A down-regulation is a specific event and not an artifact in which all G 1 cyclin expression is inhibited nonspecifically. Ectopic expression of cyclin A rescues the G 1 arrest mediated by the cyclin A inhibitory domain of MDM2 (Fig. 8) . We further show that down-regulation of MDM2 expression remarkably elevates endogenous levels of cyclin A (Fig. 4) . These observations indicate that MDM2 is involved in regulating cyclin A expression.
Analysis of the functional domain of MDM2 indicated that a SWIB region, homologous to a conserved domain of a BRG1-associated factor (36) , situated within the p53-binding domain of MDM2 was required to inhibit cyclin A expression (Fig. 5) . This observation suggests that MDM2 may compete with the BRG1 complex for p53 binding, releasing BRG1 for its repressor function. Our data (Fig. 6A and B) show that MDM2 indeed requires both p53 and BRG1 to down-regulate cyclin A.
In the absence of the cdk4 inhibitor p16, active cyclin Dcdk4 complex releases cyclin E-cdk2 activity to phosphorylate Rb and Brg1 (22) , attenuating their repressor function. Thus, the absence of p16 should also attenuate the repressor function of BRG1 after its release from p53 caused by MDM2 overexpression. Consistent with this model (22) , our data also show that silencing of p16 expression rescues MDM2-mediated down-regulation of cyclin A expression (Fig. 6C) . Conversely, silencing of MDM2 should encourage p53-BRG1 interaction by vacating the competitive binding site on p53. Therefore, up-regulation of cyclin A by silencing MDM2 did not require the presence of p16. We were able to detect transient upregulation of cyclin A after silencing MDM2 in H460 cells that do not express p16 ( Fig. 4A and B) . Our data show that although silencing of MDM2 up-regulates p21 expression, it cannot inhibit cyclin A expression efficiently when MDM2 is knocked down (Supplementary Fig. S4D ). This suggests requirement of MDM2 expression for cyclin A down-regulation. Sustained silencing of MDM2, leading to stabilization of p53, quenches MDM2 silencing and cyclin A up-regulation eventually (Fig. 4B, days 8 and 10) .
We also found that p53−/− MDM2−/− (a situation similar to silencing of MDM2 in cells with no p53 expression) earlypassage MEF cells express higher levels of cyclin A compared with MEF or p53−/− MEF cells, suggesting increase in cyclin A expression in the absence of p53 and MDM2 ( Fig. 4D and  E) . These data suggest that interaction of MDM2 with p53 family members may also have a role in down-regulation of cyclin A. It has been reported that MDM2 up-regulates p63-mediated activation of p21 promoter (47) , which could lead to downregulation of cyclin A expression in the absence of p53. Silencing of MDM2 would reverse this effect.
Based on our results, we propose a novel pathway (Fig. 10 ) that overexpression of MDM2 discourages p53-BRG1 interaction through the SWIB domain of MDM2. As reported in the literature, BRG1 released from p53 functions as a repressor of cyclin A expression. This pathway may be important after oncogenic challenges such as radiation-induced DNA damage that stabilizes p53 and up-regulates MDM2. Inhibition of p21 expression by MDM2 overexpression under such conditions would be circumvented by release of BRG1 to prevent cyclin A expression and progress of the cell cycle. The repressor function of BRG1 and thus MDM2-mediated cyclin A downregulation would be discouraged in cell lines that lack p16 expression. Consistent with our earlier observations (14), we found that the cancer cells that lack expression of functional p53, BRG1, or p16 escape the cyclin A inhibitory function of MDM2. The cell lines that are insensitive to the cyclin A inhibitory function of MDM2 are also resistant to the G 1 arrest mediated by its cyclin A inhibitory domain ( Fig. 9; ref. 14) . Because p16 is frequently deleted or methylated in cancer cells (40) , this observation explains the insensitivity of cancer cells to MDM2-mediated cyclin A down-regulation and G 1 arrest. Consistent with this argument, overexpression of cyclin A is a frequent event in cancer cells (16, 48, 49) .
It has been shown previously that MDM2−/− mouse cannot survive because of p53 accumulation (reviewed in ref.
3). Recently, Itahana et al. (50) have shown that a single amino acid mutation (C462A) at the ubiquitin ligase domain of MDM2 produces a similar lethal effect, indicating that the amino acid residues at 462 is required for controlling the lethal effect of p53 accumulation during embryogenesis. This suggests that nature would avoid a MDM2−/− or MDM2 C462A mutation.
Although interaction of MDM2 with p53 and its ubiquitination are required to prevent cell death, we report a novel p53-dependent cell cycle regulatory function of MDM2 in which MDM2 releases BRG1 by competing with p53, and a stable MDM2-p53 interaction is dispensable for restricting cyclin A expression. Our present data show that in normal cells, MDM2 is involved in regulating cell cycle by restricting cyclin A expression in cooperation with p53, p16, and BRG1. During an oncogenic challenge, induction of p53 would induce G 1 arrest and apoptosis; however, it would also up-regulate MDM2. Our data signifies that MDM2-mediated cyclin A down-regulation would provide an added level of protection from the oncogenic consequences of MDM2 overexpression. Cancer cells that lack p53, p16, or BRG1 escape this cyclin A and cell cycle restricting function of MDM2.
Our identification of a p53-dependent G 1 arrest function of MDM2 is consistent with the finding of a recent report (51) . In recent years, several oncoproteins have been shown to possess a growth arrest function (52) . Activated Ras induces senescence (53) . Raf-1 induces growth arrest that is overcome in immortal cells (54) . These observations suggest that normal cells are equipped to handle overexpression of genes that may harbor growth proliferative properties. The cancer cells that overexpress these oncoproteins have acquired genetic damages to escape the growth arrest functions of the oncoproteins.
Materials and Methods
Plasmids and MDM2 Deletion Mutants
The MDM2 cDNA and the cyclin A expression plasmids were generous gifts from Bert Vogelstein (24) and Robert Weinberg (55) . Construction of plasmids expressing MDM2 has been described in detail (7, 10) . The deletion mutant MDM2 Del 491-110 was generated by PCR by using primers flanking initiation and termination codons and inserting a NheI linker with stop codons in all three reading frames. The mutant was cloned in pGEM3zf (−) vector, sequenced, and subcloned in pCMV plasmid (7, 14) for in vivo expression.
Cells and Transfections
WI38, MRC-5, H1299, NIH3T3, and MCF-7 cells were purchased from the American Type Culture Collection and were maintained in medium as suggested by the supplier. Normal, p53−/−, and p53−/− MDM2−/− MEF cells derived from isogenic mice were kind gifts from Guillermina Lozano (32), and were cultured in DMEM in the presence of 10% fetal bovine serum. For transfection, cells were seeded 18 to 24 h before transfection at 5 × 10 5 to 6 × 10 5 cells per 10-cm dish, and plasmids or siRNAs were transfected either by the calcium phosphate method (10) or nucleofection using a nucleofector kit from Amaxa Biosystem, using the supplier's protocol. Thirty to 48 h after transfection, the cells were collected and fixed. Control (5′-CATGTCATGTGTCACATCTC-3′), BRG1 siRNA (5′-AACAUGCACCAGAUGCACAAGTT-3′), or p16 siRNA (5′-TAACCATGCCCGCATAGAT-3′) were used.
Generation of Lentivirus Vectors and Infection
Plasmids (pLKO.1) expressing short hairpin (sh) RNA against MDM2 from U6 promoter and harboring puromycin resistance gene were purchased from Open Biosystem and tested for their ability to lower MDM2 expression. The control plasmid expresses shRNA against nonendogenous luciferase gene. The lentivirus vectors were generated following a protocol provided by the supplier. For silencing, the cells were infected with respective lentiviruses for increasing time periods to determine optimum silencing.
Western Blot Analysis
Western blot analysis was carried out as described previously (10).
Immunofluorescent Staining and Confocal Imaging
Immunofluorescent staining and confocal imaging were done following a method reported by Lohrum et al. (56) . WI38 cells (2 × 10 5 ) were seeded on sterile coverslips in a six-well culture dish and were transfected with 2 μg MDM2 expression plasmid. The cells were fixed 48 h after transfection using 4% paraformaldehyde, permeabilized in ice-cold PBS containing 0.2% Triton X-100, and blocked in PBS containing 0.5% bovine serum albumin (BSA). The fixed cells were consecutively immunostained overnight at 4°C with a FITCcoupled anti-MDM2 antibody (N20, Santa Cruz Biotechnology) followed by overnight staining with a rhodamine-coupled anticyclin A antibody (SC-751 Tritc, Santa Cruz Biotechnology) in blocking solution. The slides were then washed, air dried, and mounted with Prolong Gold Antifade with 4′,6′-diamidino-2-phenylindole hydrochloride (DAPI, Molecular Probes) and analyzed under a confocal microscope (Zeiss) at 40× magnification using a LSM image browser software (Zeiss).
Flow Cytometry
Methods for cell cycle analysis have been described in detail (14) (15) (16) . Transfected cells were harvested 30 to 48 h after transfection and fixed with 70% ethanol overnight at 4°C. The fixed cells were incubated with appropriate dye-coupled antibody in PBS, 0.5% BSA, and 0.5% Tween 20. Cells were then washed thrice in PBS and 0.5% BSA. To stain DNA with 7-AAD, the cells were incubated with 20 μg/mL 7-AAD, PBS, 0.5% BSA, and 0.5% Tween 20 buffer for 90 min at 0°C in the dark. The samples were analyzed in a fluorescence activated cell sorter (Elite, Coulter or FAC Star plus , Becton Dickinson) in a flow cytometry core facility. The dye-coupled antibodies were from Santa Cruz. PE-coupled N20 was prepared using a PE conjugation kit (Phycolink) from Prozyme.
After immunostaining with fluorescent dye-coupled antibodies, relative levels of MDM2 or cyclins were determined by fluorescence intensity in the orange (575 nm) channel for PE, and green channel (525 nm) for FITC. Background fluorescence was determined by immunostaining of mock-transfected cells with FITC-or PE-coupled anti-MDM2 antibody and FITC-or PE-coupled IgG isotype of the respective cyclin antibody. The intensity of 7-AAD staining was recorded in the red (675 nm) channel. A minimum of 8,000 MDM2-overexpressing (transfected) cells was analyzed in each experiment. Experiments were repeated at least three times.
To ensure that the flow cytometric data reasonably reflect cyclin A levels, we incubated serum-starved WI38 cells with FITC-coupled anti-cyclin A antibody. Normally growing cells were also fixed and stained with FITC-coupled anti-cyclin A antibody; the cyclin A-expressing cells and cells showing basal expression were gated and analyzed by flow cytometry. Our data show that the serum-starved cells aligned with the basal level peak and did not have the cyclin A-expressing peak (Supplementary Fig. S9 ).
RNA Extraction Generation of cDNA and QPCR
Total RNA was isolated from exponentially growing cultured cell lines using the TRIzol reagent (Life Technologies, Invitrogen) following a protocol supplied by the manufacturer. The quality of RNA was checked by 1.2% agarose Tris-borate-EDTA gel electrophoresis. cDNA was synthesized using the Thermoscript reverse transcription-PCR system (Invitrogen). QPCR was done using a LightCycler system (Roche). Primers were designed using OLIGO 5 software (Molecular Biology Insights) and were synthesized by Sigma Genosys. Reactions were done in triplicate using SYBR green dye, which exhibits a higher fluorescence upon binding of double-stranded DNA. The methods have been described previously (57) . The QPCR primers used were as follows: (a) MDM2, 5′-CCCAA-GACAAAGAAGAGAGTGTGG-3′ and 5′-CTGGGCA-GGGCTTATTCCTTTTCT-3′; (b) GAPDH, 5′-GTCA-ACGGATTTGGTCGTATT-3′ and 5′-GATCTCGCTCCTG-GAAGATGG-3′; (c) human cyclin A, 5′-GACGGCGCTCCAA-GAGG-3′ and 5′-AATGGTGAACGCAGGCTGTT-3′; (d) human cyclin E, 5′-AGGTTTCAGGGTATCAGTGG-3′ and 5′-TTTGCTCGGGCTTTGT-3′; (e) human p21, 5′-TTAG-CAGCGGAACAAGGAGT-3′ and 5′-AGCCGAGAGAAAA-CAGTCCA-3′; and (f) human cyclin D1, 5′-AATGACCCC-GCACGATTTCA-3′ and 5′-CTCCCCGCTGCCACCAT-3′.
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